Inflammation and schizophrenia

Schizophrenia Bulletin

Volumn 39, Issue 6, 2013, Pages 1174-1179

  Kirkpatrick, Brian ^a   Miller, Brian J ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cytokines; First episode psychosis; Inflammation; Nonsteroidal anti inflammatory; Oxidative stress; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PSYCHOSIS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC INFLAMMATION; COMORBIDITY; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; LEUKOCYTE MIGRATION; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; TOXOPLASMOSIS; VASCULARIZATION;

CYTOKINES; FIRST-EPISODE PSYCHOSIS; INFLAMMATION; NONSTEROIDAL ANTI-INFLAMMATORY; OXIDATIVE STRESS; SCHIZOPHRENIA;

HUMANS; INFLAMMATION; SCHIZOPHRENIA;

EID: 84885997463     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt141     Document Type: Article

References (70)

1. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167:261-280.
2. Miller BJ, Culpepper N, Rapaport MH, Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:92-100.
3. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun. 2010;24:881-897.
4. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull. 2009;35:959-972.
5. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009;204:313-321.
6. Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res. 2006;56:2-13. (Pubitemid 44376487)
7. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
8. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein in schizophrenia: a review and meta-analysis [published online ahead of print February 21, 2013]. Clin Schizophr Relat Psychoses; 1-22.
9. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:993-999.
10. Miller BJ, Buckley P. Is relapse in schizophrenia an immunemediated effect? FOCUS: J Lifelong Lear Psychiatry. 2012;10:115-123.
11. Ganguli R, Gubbi A. Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia. In: Henneber AE, Kaschka WP, eds. Immunological Alterations in Psychiatric Diseases. Adv Biol Psychiatry, Vol. 18. Basel, Switzerland: Karger; 1997:35-43.
12. McAllister CG, van Kammen DP, Rehn TJ, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152:1291-1297.
13. Nikkilä HV, Müller K, Ahokas A, Miettinen K, Rimón R, Andersson LC. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry. 1999;156:1725-1729. (Pubitemid 29517564)
14. Nikkilä HV, Müller K, Ahokas A, Rimón R, Andersson LC. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res. 2001;49:99-105. (Pubitemid 32434317)
15. Busse S, Busse M, Schiltz K, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun. 2012;26:1273-1279.
16. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50:1801-1807.
17. van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative ®-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820-822.
18. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151-157. (Pubitemid 350061255)
19. Steiner J, Mawrin C, Ziegeler A, et al. Distribution of HLADR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006;112:305-316. (Pubitemid 44275885)
20. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721-3728.
21. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22:83-93. (Pubitemid 41831607)
22. Ezeoke A, Mellor A, Buckley P, Miller BJ. A systematic, quantitative review of blood autoantibody elevations in schizophrenia [published online ahead of print August 14, 2013, pii: S0920-9964(13)00373-3]. Schizophr Res. doi: 10.1016/j. schres.2013.07.029.
23. Miller BJ, Graham KL, Bodenheimer CM, Culpepper NH, Waller JL, Buckley PF. A prevalence study of urinary tract infections in acute relapse of schizophrenia. J Clin Psychiatry. 2013;74:271-277.
24. Fillman SG, Cloonan N, Miller LC, Weickert CS. Markers of inflammation in the prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18:133.
25. Miller B, Mellor A, Buckley PF. Interleukin-6 and cognition in non-affective psychosis. Schizophr Bull. 2013;39:S242-S243.
26. Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 2011;72:1677-1684.
27. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012;198:212-215.
28. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res. 2000;44:165-175. (Pubitemid 30657953)
29. Liu H, Kang Y, Liang J, et al. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012;198:329-331.
30. Zhang XY, Cao LY, Song C, et al. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology. 2008;201:383-389.
31. Nitta M, Kishimoto T, Müller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials [published online ahead of print May 29, 2013]. Schizophr Bull. doi: 10.1093/schbul/sbt070.
32. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31:287-292.
33. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138-149.
34. Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res. 2013;149:88-95.
35. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878-893.
36. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361-368.
37. Amminger GP, Schäfer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
38. Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004;161:889-895. (Pubitemid 38625343)
39. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun. 2001;15:411-420. (Pubitemid 34044524)
40. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci. 2009;3:14.
41. Samuelsson AM, Jennische E, Hansson HA, Holmäng A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1345-R1356.
42. Borrell J, Vela JM, Arévalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology. 2002;26:204-215. (Pubitemid 34093083)
43. Pacheco-López G, Giovanoli S, Langhans W, Meyer U. Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr Bull. 2013;39:319-329.
44. Romero E, Ali C, Molina-Holgado E, Castellano B, Guaza C, Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology. 2007;32:1791-1804. (Pubitemid 47076375)
45. Romero E, Guaza C, Castellano B, Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry. 2010;15:372-383.
46. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400-409.
47. Hanifi-Moghaddam P, Schloot N, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes. 2003;52:1137-1142. (Pubitemid 36523347)
48. Yao JK, van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol. 2004;59:297-326. (Pubitemid 39753905)
49. Sardi F, Fassina L, Venturini L, et al. Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev. 2011;11:149-153.
50. Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol. 1989;28:86-88.
51. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012;10:66.
52. Moon ML, McNeil LK, Freund GG. Macrophages make me sick: how macrophage activation states influence sickness behavior. Psychoneuroendocrinology. 2011;36:1431-1440.
53. Dowlati Y, Herrmann N, Swardfager W, et al. A metaanalysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
54. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31-41.
55. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience. 1999;88:823-836. (Pubitemid 28518260)
56. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokinespecific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994;643:40-49. (Pubitemid 24115074)
57. Zalcman S, Savina I, Wise RA. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res. 1999;847:276-283.
58. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol. 2009;23:287-294.
59. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315-322. (Pubitemid 41713657)
60. Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India. 2000;48:231-238.
61. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37:1147-1156.
62. McCusker RH, Kelley KW. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol. 2013;216:84-98.
63. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res. 2009;167: 66-72.
64. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. Ann Thorac Surg. 2001;71:1512-1517.
65. Kleine TO, Benes L, Zöfel P. Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull. 2003;61:265-279. (Pubitemid 36952473)
66. Gaughran F, O'Neill E, Sham P, Daly RJ, Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophr Res. 2002;56:235-239. (Pubitemid 34628814)
67. Martínez-Gras I, García-Sánchez F, Guaza C, et al. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res. 2012;200: 1022-1025.
68. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res. 2006;84:180-182.
69. O'Connor MF, Bower JE, Cho HJ, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23:887-897.
70. Prasad KM, Eack SM, Keshavan MS, Yolken RH, Iyengar S, Nimgaonkar VL. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull. 2013;39:857-866.